Dublin, Nov. 24, 2021 (GLOBE NEWSWIRE) -- The "Targeted Oncology Therapeutics: Breast Cancers" report has been added to ResearchAndMarkets.com's offering.
Treatments for breast cancer have too often focused on interventional methods that leave patients emotionally and physically scarred. That scenario is now changing as clinicians increasingly utilize targeted methods for treating breast neoplasms.
The active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols.
More than a dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the therapeutic drugs and the biomarkers they utilize.
What You Will Learn
What is the market share of approved therapeutics?
What is the global supply picture for targeted therapeutics?
Who are the market leaders, by Indication, by Product?
What is the therapeutic coverage across all oncology indications?
What are the product opportunities?
What are the established products in this space by target, indication, API class, revenue?
What is the competitive picture for the major Oncology market segments?
Drug treatment resources
Competitive therapy map
Clinical trial activity
Who are the leading competitors in the field of next-generation therapeutics?
Key Topics Covered:
The Recombinant Drug Ecosystem
Biological Drug Activity by Region
Biological Oncology Market Leaders
Oncology mAbs: Competitive Considerations
mAbs and Targeted Oncology Therapeutics
Historical Growth of Biologicals
Leading Biological Drug Companies - Activity by Drug & Segment
FDA Approved mAbs Indicated for Oncology (Ado to Bre)
FDA Approved mAbs Indicated for Oncology (Cem to Ipl)
FDA Approved mAbs Indicated for Oncology (Mog to Pol
FDA Approved mAbs Indicated for Oncology (Ram to Tra)
Drugs Indicated for Specific Breast Cancers
Targeting Drugs Approved for Treating Breast Cancers
Tyrosine Kinase Inhibitors
The Addressable Market
Drugs in Development
Leading Breast Cancer Supplier Assessments
For more information about this report visit https://www.researchandmarkets.com/r/7zs6a3
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900